| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8679666 | Thrombosis Research | 2018 | 10 Pages |
Abstract
This review supports the use of PCC for VKA reversal, specifically for 4F-PCC over FFP for laboratory reversal. There are no studies on clinical efficacy of non-specific agents for DOAC reversal and the evidence for laboratory reversal is not consistent.
Keywords
TTRrFVIIaSwedish KronorSEKECTVKAFFPINRVTEaPCCETPOACFXaDTTAPTTFIIaDOACPCCvitamin K antagonistsvitamin K antagonistThromboembolismVenous thromboembolismprothrombin complex concentrateIntracranial hemorrhageSBUactivated partial thromboplastin timeTime in therapeutic rangeecarin clotting timeprothrombin timeoral anticoagulantDirect oral anticoagulantDirect oral anticoagulantsRecombinant activated factor VIIactivated Factor XAtrial fibrillationICHInternational Normalized RatioReversalendogenous thrombin potentialfresh frozen plasma
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Max Tornkvist, J. Gustav Smith, Ashkan Labaf,